Confluence Discovery Technologies
Confluence Discovery Technologies is a full-service drug discovery research organization specializing in cell and molecular biology, biochemistry, enzymology, biomarker development, immunology, in vivo efficacy models, and medicinal chemistry. As an indirectly wholly owned subsidiary of Aclaris Therapeutics, Inc., it provides expert scientific research and tailored solutions to pharma and biotech companies, aiming to expedite drug development from idea to IND and market.
Industries
Nr. of Employees
small (1-50)
Confluence Discovery Technologies
St Louis, Missouri, United States, North America
Services
Enzyme and cellular assay development, kinetics, binding studies, high-throughput translation and mechanistic inhibitor analysis provided as laboratory services.
Primary cell and cell-line based assay development, cloning and expression, intracellular and secreted analyte measurement, and signal transduction pathway analysis.
Design and execution of custom biochemical and cellular assays, specialty screens, HTS-ready formats, liquid handling integration and bespoke data analysis.
Development of target, functional, disease and safety biomarkers, assay validation and transfer from preclinical matrices to clinical testing.
In vitro and in vivo immune functional assays including T cell assays, ADCC/CDC assays, immunophenotyping and cytokine profiling to support immuno-oncology programs.
Rodent efficacy models, ADME studies, acute pharmacology, PK/PD analysis and rapid in vivo assays for correlating exposure with pharmacodynamic effects.
Enzyme and cellular assay development, kinetics, binding studies, high-throughput translation and mechanistic inhibitor analysis provided as laboratory services.
Primary cell and cell-line based assay development, cloning and expression, intracellular and secreted analyte measurement, and signal transduction pathway analysis.
Design and execution of custom biochemical and cellular assays, specialty screens, HTS-ready formats, liquid handling integration and bespoke data analysis.
Development of target, functional, disease and safety biomarkers, assay validation and transfer from preclinical matrices to clinical testing.
In vitro and in vivo immune functional assays including T cell assays, ADCC/CDC assays, immunophenotyping and cytokine profiling to support immuno-oncology programs.
Rodent efficacy models, ADME studies, acute pharmacology, PK/PD analysis and rapid in vivo assays for correlating exposure with pharmacodynamic effects.
Expertise Areas
- Drug discovery from idea to IND
- Enzymology and biochemical screening
- Cellular and molecular biology
- Biomarker development and translational biology
Key Technologies
- High-throughput screening (plate-based, 96/384)
- Bead-based multiplex immunoassays
- Electrochemiluminescent multiplex immunoassays
- Surface plasmon resonance (SPR) biosensor assays
News & Updates
Participation in a drug discovery event at ABI Labs, Natick, MA, including a lunch and learn session.
Research efforts and posters presented at Society for Laboratory Automation & Screening (SLAS) conferences.
Participation in a drug discovery event at ABI Labs, Natick, MA, including a lunch and learn session.
Research efforts and posters presented at Society for Laboratory Automation & Screening (SLAS) conferences.